DGAP-Adhoc: Epigenomics AG appeals recent FDA request for

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Nov 25, 2015 at 4:45 PM

DGAP-Adhoc: Epigenomics AG appeals recent FDA request for additional information

Epigenomics AG / Key word(s): Miscellaneous 25.11.2015 22:41 Dissemination of an Ad hoc announcement according to Â§ 15 WpHG, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Ad Hoc Announcement pursuant to Sec. 15 WpHG (German Securities Trading Act) Epigenomics AG appeals recent FDA request for additional information Berlin, Germany, November 25, 2015 - Epigenomics AG, Berlin, Germany, (Frankfurt Prime Standard: ECX; ISIN: DE000A11QW50) the German-American cancer molecular diagnostics company, today announced that after discussions with FDA in relation to its premarket approval (PMA) application for the Company's blood-based colorectal cancer (CRC) screening test Epi proColon(R), it is appealing the agency's decision on additional data requirements. Epigenomics is requesting a supervisory review of the recent decision to require additional clinical data to support PMA approval. Epigenomics believes that an approval for the intended use of Epi proColon(R) is warranted based on the data that has been submitted to date. The Company has provided an extensive amount of data under its PMA application and received a favorable recommendation by the FDA Medical Device Advisory Committee in March 2014. Furthermore, in its appeal, Epigenomics has highlighted the difficulties to measure adherence in the intended use population under the existing regulatory framework along with a willingness to work with FDA to design an appropriate post-approval study. FDA regulations provide several mechanisms to applicants for further review of the agency's actions. A request for supervisory review is directed to the next organizational level above the level at which the decision was made. Based on respective guidelines and following discussions with FDA, Epigenomics believes the supervisory review will be completed in Q1 2016. Any decision on the company's appeal does not affect to the right of Epigenomics to amend its PMA application in the future. - End of Ad hoc - Contact Epigenomics AG Peter Vogt, Investor & Public Relations Epigenomics AG GeneststraÃe 5 10829 Berlin Phone +49 (0) 30 24345 386 ir@epigenomics.com www.epigenomics.com Epigenomics legal disclaimer This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. The information contained in this communication does not constitute nor imply an offer to sell or transfer any product, and no product based on this technology is currently available for sale by Epigenomics in the United States or Canada. The analytical and clinical performance characteristics of any Epigenomics product based on this technology which may be sold at some future time in the U.S. have not been established. 25.11.2015 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Epigenomics AG GeneststraÃe 5 10829 Berlin Germany Phone: +49 30 24345-0 Fax: +49 30 24345-555 E-mail: ir@epigenomics.com Internet: www.epigenomics.com ISIN: DE000A11QW50 WKN: A11QW5 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Bank Leumi Q3 Earnings Preview: Key Dates & Insights

A Closer Look at Bank Leumi's Upcoming Q3 Release Take a seat, folks. Bank Leumi’s gearing up to spill the beans on their Third Quarter 2026 earnings come November 17th. If you’re in the financial world, you might want to mark your calendar because these reports tend to shake things up. You know how these go - numbers rolling out, market responses, and plenty of...

Domino’s Faces Legal Heat: Investors' Eyes On DPZ

Domino's Pizza Under the Legal Microscope Picture this, folks: Domino's Pizza (NASDAQ: DPZ) is caught in a legal whirlwind that might give its shareholders a rollercoaster of a read in the coming weeks. On the docket is a serious probe led by Johnson Fistel, a law outfit with quite the reputation for defending shareholder interests. The focus? Whether certain hot shots at...

xTool X1: Redefining Laser Fabrication for Makers

The Next Generation of Laser Fabrication Whenever a new gizmo hits the market, it's usually just an upgrade in disguise—faster, shinier, a touch more wattage. Not this time. xTool shook things up by rolling out the X1, a laser platform that gets what small businesses and makers truly crave: versatility and long-lasting potential. This bad boy does more than engrave; it...

BD's New Liverty™ TIPS Stent: A Game Changer?

Could This Be the Breakthrough for Portal Hypertension? Now, here's something that might just turn a few heads in the medical world. BD has launched their Liverty™ TIPS Stent Graft in the U.S., a move set to shake up the landscape for treating portal hypertension. This isn't just another shiny new gadget—it's a promise of more personalized patient care in a field...

BASIS Bellevue Expands with New K-4 Campus

A New Era for Young Learners in Bellevue When a community-driven school like BASIS Independent Bellevue makes a move to expand, it doesn't happen in a vacuum. They're not just building another campus—they're aiming to sculpt the future right here in Bellevue, and boy, do they have a plan. The new Lower School campus opening come Fall 2027 is dedicated to kiddos in...

EzAccounting: Your Q3 IRS Filing Gets a No-Nonsense Tool

Taking Tax Deadlines Head-On Tax season's got businesses sweating all over the country, but it doesn't have to be a full-scale panic attack if you've got the right gear. That's where ezAccounting steps in, dishing out a reliable solution to hit those looming IRS Form 941 deadlines without a migraine. By November 2, 2026, companies are looking to dodge the bullet of...

Amgen Q3 2026 Results: What Investors Should Know

Amgen Prepares to Reveal Third Quarter 2026 Financials If there's one thing I've learned about investing, it's that the devil's in the details, and Amgen's (NASDAQ:AMGN) upcoming webcast for its third quarter 2026 financial results is exactly the kind of detail that sets market-watchers' hearts racing. Scheduled for November 3, just after the U.S. markets close, this is...

California Cash Surplus Raises Investor Eyebrows

California's Unexpected Financial Bounty Kicking things off with a real humdinger: California's September cash flow exceeded expectations by a whopping $2.9 billion. That's not chump change, folks. It's like finding an extra twenty in your coat pocket but on a much grander scale. Impressively, the state's General Fund receipts tallied up to $22.9 billion, surpassing the...

York Space Systems Faces Turbulence Amid Investor Lawsuit

York's Shaky Strategy Under the Microscope How do you go from sky-high ambitions to a grinding halt in a matter of weeks? This ain’t your typical Wall Street plot twist—it involves York Space Systems, or NYSE:YSS. These guys promised dominance in the Space Development Agency’s Transport Layer program, only to have their shooting star come crashing down. And now,...

Review Insurance Coverage After Major Life Changes

Why Life Changes Demand an Insurance Review The nitty-gritty of life doesn't sit still—marriages, babies, job changes, and home deals or steals each bring their own clutter to the table. One thing's for sure: when your life shifts, your insurance ought to keep pace. Insurance Agent Nick Hogan drops the dime in the latest HelloNation article, laying it bare why...